Forest switches to Namenda XR ahead of patent expiry
This article was originally published in Scrip
Executive Summary
Forest Laboratories will not wait for generic competition to cut into its Namenda (memantine) sales in 2015; the company will pull the twice-daily pills from the market in August to boost physician and patient uptake for the extended-release version of the Alzheimer's drug.